Skip to content

Home
About Us
Office
E-Library
Research Support
Blog
Donation
Contact Us

Home
About Us
Office
E-Library
Research Support
Blog
Donation
Contact Us

June 24, 2024

New Releases from NCBI BookshelfBelumosudil (Rezurock): CADTH Reimbursement Review: Therapeutic area: Graft-versus-host disease [Internet].Belumosudil (Rezurock): CADTH Reimbursement Review: Therapeutic area: Graft-versus-host disease [Internet].

Leave a Comment / Uncategorized /

Post Content

New Releases from NCBI BookshelfIbrutinib (Imbruvica): CADTH Reimbursement Review: Therapeutic area: Waldenström macroglobulinemia [Internet].Ibrutinib (Imbruvica): CADTH Reimbursement Review: Therapeutic area: Waldenström macroglobulinemia [Internet].

Leave a Comment / Uncategorized /

Post Content

New Releases from NCBI BookshelfVutrisiran (Amvuttra): CADTH Reimbursement Review: Therapeutic area: Hereditary transthyretin-mediated amyloidosis [Internet].Vutrisiran (Amvuttra): CADTH Reimbursement Review: Therapeutic area: Hereditary transthyretin-mediated amyloidosis [Internet].

Leave a Comment / Uncategorized /

Post Content

New Releases from NCBI BookshelfEvinacumab (Evkeeza): CADTH Reimbursement Review: Therapeutic area: Homozygous familial hypercholesterolemia [Internet].Evinacumab (Evkeeza): CADTH Reimbursement Review: Therapeutic area: Homozygous familial hypercholesterolemia [Internet].

Leave a Comment / Uncategorized /

Post Content

New Releases from NCBI BookshelfInebilizumab (Uplizna): CADTH Reimbursement Recommendation: Indication: As monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (NMOSD) who are anti-aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive [Internet].Inebilizumab (Uplizna): CADTH Reimbursement Recommendation: Indication: As monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (NMOSD) who are anti-aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive [Internet].

Leave a Comment / Uncategorized /

CADTH recommends that Uplizna be reimbursed by public drug plans for the treatment of neuromyelitis optica spectrum disorder (NMOSD), if

New Releases from NCBI BookshelfLiving with ALS [Prepublication Draft].Living with ALS [Prepublication Draft].

Leave a Comment / Uncategorized /

At any one time, at least 30,000 people in the U.S. are living with amyotrophic lateral sclerosis (ALS), a rapidly

← Previous 1 2

Useful Links

NEWREDMARS SKILL AND RESEARCH FOUNDATION

Registration No: 771800548 Contact Number : +91-8249516996

Publication
Skill Development
Blog Writing

Research
Awareness Camp
Digital Research

Ngo Darpan
Service
Donation

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.

Term and Condition
Privacy Policy
Disclaimer

Scroll to Top